Dr. Reddys Laboratories Ltd.

Dr. Reddy's Laboratories has launched Quetiapine fumarate tablets (25mg, 50mg, 100mg, 200mg, 300mg and 400mg), a bioequivalent version of SEROQUEL tablets in the US market on March 27, 2012 following the approval by the United States Food & Drug Administration (USFDA) of the company’s ANDA for Quetiapine fumarate tablets.

The SEROQUEL brand has US sales of approximately $4.6 billion for the most recent twelve months ending December 2011 according to IMS Health.

Dr. Reddy's Quetiapine fumarate tablets in 25mg and 50mg are available in 100 and 500 count bottle sizes, 100mg, 200mg and 400mg are available in 100 count bottle sizes and 300mg is available in 60 count bottle sizes.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.